- 询价
- Agrisera
- Sweden
- AS20 4474
- 2026年01月12日
- Immunohistochemistry (IHC)
- Chicken
- Peptostreptococcus magnus
企业认证
相关产品推荐更多 >
Anti-PRK ribulose-5-P-kinase | Phosphoribulokinase, DyLight® 488 conjugated (40 µg)
询价
Goat anti-Mouse IgG (H&L), F(ab)'2 Fragment, ALP conjugated, min, cross-reactivity to bovine, goat, human, rabbit, or rat IgG (highly absorbed against rat IgG)
询价Chicken anti-Mouse IgG (H&L), min, cross-reactivity to human or rabbit IgG/serum proteins
询价H3K9ac | Histone H3, acetylated lysine 9
询价Anti-APP-C31 | Caspase 3 cleaved APP, C terminal fragment
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant protein L
- 形态：
Immunogen affinity purified in PBS. Contains 50% Glycerol with 0.075% sodium azide, conjugated to FITC.
- 保存条件：
Store at -20°C; make aliquots to avoid repeated freeze-thaw cycles. Please remember to spin the tubes briefly prior to opening them to avoid any losses that might occur from material adhering to the cap or sides of the tube.
- 克隆性：
Polyclonal
- 适应物种：
Peptostreptococcus magnus
- 供应商：
Agrisera
- 宿主：
Chicken
- 应用范围：
Immunohistochemistry (IHC)
- 靶点：
Anti-Peptostreptococcal Protein L, FITC-conjugated
- 抗体英文名：
Anti-Peptostreptococcal Protein L, FITC-conjugated
- 抗体名：
Anti-Peptostreptococcal Protein L, FITC-conjugated
- 规格：
0.5 mg
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验min。②荧光素的准备 根据欲标记的蛋白质总量，按每毫克免疫球蛋白加0．01mg荧光色素，用分析天平准确称取所需的异硫氰酸荧光素粉末。也可用下述公式计算出免疫球蛋白、荧光素的量，还可以算出需加缓冲液的量。a．蛋白溶液：含量Amg／m1；容积Bml。b．总蛋白量(AXB)＝Crag。c．C／20～C／10＝Dmg(如蛋白含量低于20mg／ml，用C／10；如高于20mg／ml，用C／20)。d．荧光素FITC的量：(1／50～2／100)XC＝Emg。e．巳0．5mol／L(pH9．5)碳酸盐缓冲
Anti-claudin-4, whose corresponding antigen receptors are known to be overexpressed in both primary and metastatic human pancreatic cancer, is utilized for targeted delivery and imaging of pancreatic cancer. In this protocol
Analysis and Purification of Antibody Fragments Using Protein A, Protein G, and Protein L
Today, monoclonal antibodies (mAbs) form the largest category of biopharmaceuticals in clinical trials and their number is expanding rapidly (DataMonitor 2007). The antibodies or functional antibody fragments are being produced in artificial
技术资料暂无技术资料 索取技术资料
